Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

This phase I study assessed the intrapulmonary pharmacokinetic profiles of relebactam (MK-7655), a novel β-lactamase inhibitor, and imipenem. Sixteen healthy subjects received 250 mg relebactam with 500 mg imipenem-cilastatin, given intravenously every 6 h for 5 doses, and were randomized to broncho...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizk, Matthew L., Rhee, Elizabeth G., Jumes, Patricia A., Gotfried, Mark H., Zhao, Tian, Mangin, Eric, Bi, Sheng, Chavez-Eng, Cynthia M., Zhang, Zufei, Butterton, Joan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826112/
https://www.ncbi.nlm.nih.gov/pubmed/29311084
http://dx.doi.org/10.1128/AAC.01411-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826112/
https://www.ncbi.nlm.nih.gov/pubmed/29311084
http://dx.doi.org/10.1128/AAC.01411-17

Ejemplares similares